Publicaciones en colaboración con investigadores/as de Pfizer (United States) (205)

2024

  1. Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain

    PharmacoEconomics - Open, Vol. 8, Núm. 2, pp. 291-302

  2. Estimated Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain, 2016–2019

    Infectious Diseases and Therapy

  3. Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study

    European Journal of Cancer, Vol. 196

2023

  1. Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

    Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4166-4177

  2. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 8, pp. 1557-1568

  3. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning

    Thrombosis Research, Vol. 228, pp. 181-188

  4. Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: A pooled analysis from the Phase 3 clinical trial programme

    Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 11, pp. 2672-2682

  5. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

    Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267

  6. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

    Clinical and Translational Oncology

  7. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

    Rheumatology and Therapy, Vol. 10, Núm. 2, pp. 357-373

  8. Preference of acromegaly patients for treatment attributes in Spain

    Endocrine, Vol. 82, Núm. 2, pp. 379-389

  9. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia

    European Respiratory Review, Vol. 32, Núm. 170

  10. The role of diagnostic tests in antifungal stewardship for treating invasive fungal infections: A plain language summary

    Future Microbiology, Vol. 18, Núm. 1, pp. 9-13

2022

  1. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 282-293

  2. Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System

    ClinicoEconomics and Outcomes Research, Vol. 14, pp. 149-161

  3. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  4. Comorbidity identification and referral in atopic dermatitis: a consensus document

    Journal of Dermatological Treatment, Vol. 33, Núm. 5, pp. 2643-2653

  5. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib

    npj Precision Oncology, Vol. 6, Núm. 1

  6. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 1, pp. 73-83

  7. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain

    Journal of Medical Economics, Vol. 25, Núm. 1, pp. 840-847